Schedules of Controlled Substances Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol (-)-delta-9-transtetrahydrocannabinol (delta-9-THC) in Schedule II. Interim final rule, with request for comments.
On July 1, 2016, the U.S. Food and Drug Administration (FDA) approved a new drug application for Syndros, a drug product consisting of dronabinol (-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC) oral solution. Thereafter, the Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation that would result in Syndros (and other oral solutions containing dronabinol) being placed in schedule II of the Controlled Substances Act (CSA). In accordance with the CSA, as revised by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing FDA-approved products of oral solutions containing dronabinol in schedule II of the CSA.